Shots:  TULIP-SC full results reinforce efficacy and remission potential with subcutaneous Saphnelo, showing higher disease activity reduction (56.2% vs 34% placebo at Week 52), improved BICLA response, DORIS-defined remission, and reduced oral corticosteroid use, consistent with the IV formulation  Self-administration expands access and adherence, offering flexible at-home or clinic dosing, supporting earlier biologic intervention and steroid…